Evaluating the effectiveness of amphotericin B and azoles for invasive fungal infections
A Retrospective Clinical Study on the Efficacy and Safety of Amphotericin B Compared With Azoles in the Treatment of Invasive Fungal Disease
This study looks at how well amphotericin B and azole antifungals work and how safe they are for patients with invasive fungal infections based on their medical records.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Sex | All |
| Sponsor | Sichuan Provincial People's Hospital Academic / other |
| Locations | 1 site (Chengdu, Sichuan) |
| Trial ID | NCT06819410 on ClinicalTrials.gov |
What this trial studies
This study collects and analyzes medical records and clinical data of patients diagnosed with invasive fungal disease who have been treated with amphotericin B or azole antifungals. The data is gathered from the electronic medical record system of Sichuan Provincial People's Hospital over a period from 2021 to 2024. The primary focus is to assess the efficacy and safety of these antifungal treatments in real-world clinical settings.
Who should consider this trial
Good fit: Ideal candidates for this study are patients of any age or gender who have been diagnosed with invasive fungal disease and treated with polyene or azole antifungals for at least 7 days.
Not a fit: Patients with incomplete data or those deemed unsuitable by the investigator will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the most effective treatment options for invasive fungal infections, potentially improving patient outcomes.
How similar studies have performed: While this study focuses on a specific patient population and treatment regimen, similar studies evaluating antifungal therapies have shown promising results in improving treatment outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * There is no age limit, gender is not limited * Patients with invasive fungal disease who are treated with polyene antifungals or azole antifungals should be treated for ≥ 7 days. Exclusion Criteria: * Patients with incomplete data or other factors affecting the clinical outcome judgement * Patients who are judged by the investigator to be unsuitable to participate in this study.
Where this trial is running
Chengdu, Sichuan
- Sichuan Provincial People's Hospital — Chengdu, Sichuan, China (Recruiting)
Study contacts
- Study coordinator: lingai Pan, PhD
- Email: panlingai2004@163.com
- Phone: 17708130236
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.